Dr. Heidi Overton was featured in a recent press conference where President Trump signed an executive order concerning the childhood vaccination schedule. This event took place on August 10. President Trump later announced on Truth Social that he is nominating Dr. Overton to be the next FDA commissioner. She is expected to fill the vacancy left by Dr. Marty Makary, who resigned after 13 months on the job.
Dr. Overton is a trained surgeon and currently serves as the deputy assistant to the president for domestic policy at the White House. Her nomination raises discussions about the transition from a White House position to a bureaucratic role at the FDA. Dr. Joshua Sharfstein, former principal deputy commissioner at the FDA under the Obama administration, remarked on the potential adjustments involved in shifting to such a role. At the FDA, Overton will engage with scientists skilled in assessing the safety of medications and comprehending varying perspectives within the agency.
In any administration, there are White House advisers who are walking around saying, ‘Why can’t FDA just do this? What FDA should really do is that,’he says, emphasizing the need to understand the agency’s intricacies.
Managing the FDA is often seen as the most challenging health-related position in the government. It has around 18,000 employees and regulates food, drugs, and medical devices alongside other products like tobacco and cosmetics. Successful commissioners, as noted by Sharfstein, require both intellect and resilience to withstand numerous political, business, and advocacy pressures.
Dr. Overton’s previous work at the conservative America First Policy Institute included opposition to gender-affirming care for minors. She also questioned the safety of medication abortion, disagreeing with the FDA’s approval of its prescription via telehealth.
On August 10, Trump issued an executive order revising the childhood vaccine schedule, reviving debunked links between vaccines and autism. During her remarks, Overton endorsed the order as a “historic action.” She supported developing separate vaccines for measles, mumps, and rubella, each currently combined in the MMR or MMRV vaccine.
Overton stated, “We do still recommend the measles vaccine for all children, but we want parents to be informed about the timing and to have the option to separate them out.” Public health experts, including Sharfstein, have criticized this approach for lacking scientific support. Separating these vaccinations could inflate costs and risk incomplete dosage schedules for children.
For Overton to become FDA commissioner, she needs Senate confirmation. Sen. Patty Murray, D-Wash., has pledged to vote against her nomination. Meanwhile, Sen. Bill Cassidy, a Republican from Louisiana, has expressed concerns but hasn’t announced his voting intention. NPR attempted to arrange an interview with Overton through the White House but did not receive a response before publication.